This clear tumour-driving effect has highlighted fibulin-3 as a putative therapeutic target in glioma/glioblastoma, in which it may be possible to impair tumour progression through suppression of fibulin-3 activity at either the gene, mRNA, or protein level (Figure 6). The gene discussed is EFEMP1; the disease is central nervous system cancer.